Results
A total of 824 records were initially identified and screened at title/abstract level. Of these, 104 full-text articles were assessed for eligibility, of which 11 studies [ 7 – 17 ] were included and added to the 10 studies [ 1 , 2 , 18 – 25 ] from the previous SR [ 3 ]. Overall, 21 studies, gathering 2,804 patients in total, matched our eligibility criteria (see Fig. 1 ).
Table 1 Description of the included studies and patients by specialties Year Country Authors PMID Specialty Oncology Design Type of procedures Patient number AIRSEAL ® vs. Control Age (year) AIRSEAL ® vs. Control Female (%) AIRSEAL ® vs. Control BMI (kg/m²) AIRSEAL ® vs. Control 2011 USA Herati et al. [ 25 ] 20,888,033 Urology Yes PNRCT Renal surgery 26 vs. 25 61.6 ± 14.2 vs. 59.7 ± 14.3 46.2 vs. 40 30.8 ± 6.3 vs. 29.3 ± 7.3 2013 Switzerland Horstmann et al. [ 2 ] 23,186,377 Urology Yes PNRCT Radical Prostatectomy 19 vs. 17 64 vs.65 0 vs. 0 28 vs. 26 2015 USA George et al. [ 26 ] 25,725,807 Urology Yes Retro Prostatectomy 257 vs. 385 62.3 (32.1–76.6) vs. 62.6 (42.7–75.4) 0 vs.0 27.6 (16.2–47.4) vs. 27.3 (17.8–41.4) 2016 USA Bucur et al. [ 1 ] 27,130,263 Urology Yes RCT Renal surgery 28 vs. 28 62.5 (15.3) vs. 64.8 (13.1) 17.9 vs. 35.7 27.9 (6.2) vs. 28.7 (4.1) 2017 Italy Annino et al. [ 22 ] 27,495,337 Urology Yes PNRCT Partial nephrectomy 67 vs. 55 66.3 vs. 67.1 29.9 vs. 25.5 na vs. na 2017 Italy Covotta et al. [ 21 ] 28,452,822 Urology Yes RCT Cystectomy 28 vs. 28 60.2 (6.5) vs. 61.1 (9.1) 28.6 vs. 28.6 25.9 (3.5) vs. 26.5 (3.9) 2019 USA Shahait et al. [ 19 ] 30,740,014 Urology Yes PNRCT Radical Prostatectomy 100 vs. 100 62 ± 7 vs. 62 ± 7 0 vs. 0 28.5 ± 4.2 vs. 27.2 ± 4.5 2021 USA Feng et al. [ 8 ] 32,632,561 Urology Yes RCT Partial nephrectomy 31 vs. 31 31 60.1 (11) vs. 61.0 (11.6) / 60.4 (12) 39 vs. 39 / 42 30.0 (5.2) vs. 28.7 (5.7) / 31.0 (5.31) 2021 USA Abaza et al. [ 9 ] 33,349,135 Urology Yes RCT Prostatectomy 50 vs. 50 61 ± 5.6 vs. 62 ± 6.7 0 vs. 0 29.1 ± 4.3 vs. 28.3 ± 3.3 2021 USA Desroches et al. [ 10 ] 33,577,899 Urology Na RCT Partial nephrectomy 66 vs. 66 69 60.1 (13.3) vs. 60 (12.5) / 60.1 (11.8) 35 vs. 35 / 38 29.2 (6.0) vs. 28.9 (5.6) / 31.2 (5.6) 2023 Lebanon Ayoub et al. [ 14 ] 37,704,868 Urology Yes Retro Radical Prostatectomy 125 vs. 201 65.1 ± 6.6 vs. 63.7 ± 7.3 0 vs. 0 28.8 ± 4.2 vs. 28.4 ± 5 2023 Italy Forte et al. [ 15 ] 37,440,928 Urology Yes Retro Partial nephrectomy 14 vs. 13 61.3 vs. 65.9 21.4 vs. 30.7 na vs. na 2024 China Wei et al. [ 17 ] 38,381,369 Urology Yes RCT Partial nephrectomy 31 vs. 31 53 (48; 64) vs. 57 (44; 63) 35.5 vs. 45.2 25.4 (22.7–27.7) vs. 24.3 (22.6–27.0) 2024 USA Chien et al. [ 16 ] 37,819,689 Urology No Retro Pyeloplasty 14 vs. 12 8.8 (3.7–15.6) vs. 8.9 (4.6–17.6) 28.6 vs. 41.7 17.3 (16.4–22.3) vs. 16.5 (15.0–19.1) 2016 Japan Miyano et al. [ 23 ] 28,029,370 Abdominal No PNRCT Appendectomy 18 vs. 21 7.4 vs. 8.1 na vs. na na vs. na 2021 USA Paull et al. [ 7 ] 32,333,365 Abdominal Yes Retro LAR Right hemicolectomy 40 vs. 54 24 vs. 32 55.2 ± 15.4 vs. 58.4 ± 9.7 55.5 ± 18.2 vs. 64.2 ± 13.2 55.0 vs. 42.6 70.8 vs. 46.9 27.9 ± 7.8 vs. 28.4 ± 6.5 29.7 ± 7.5 vs. 29.1 ± 7.3 2021 Austria Luketina et al. [ 11 ] 32,767,145 Abdominal No RCT Cholecystectomy Sigmoid resection 96 vs. 97 54.0 ± 12.9 vs. 55.2 ± 13.2 54.2 vs. 54.6 27.4 (24.6–31.0) vs. 27.8 (24.8–30.1) 2017 France Sroussi et al. [ 20 ] 28,403,972 Gynecology No RCT Tubal patency test Salpingectomy 30 vs. 30 33 (19–45) vs. 35 (25–58) 30 vs. 30 22.1 (19-29.4) vs. 22.6 (19.3–31.2) 2020 USA Madueke-Laveaux et al. [ 18 ] 31,125,720 Gynecology No RCT Uterine myomas Endometriosis 33 vs.33 33 vs.33 40 ± 9 vs. 40 ± 7 39 ± 7 vs. 36 ± 8 100 vs. 100 27 ± 6 vs. 28 28 ± 7 vs. 27 2022 France Delecourt et al. [ 13 ] 35,569,811 Gynecology No RCT Hysterectomy for benign condition 40 vs. 40 48.5 (7) vs. 46.5 (6) 100 vs. 100 25.3 (9.3) vs. 25.5 (5.5) 2022 Italy Buda et al. [ 12 ] 35,327,010 Gynecology Yes Retro Early-stage endometrial cancer 84 vs. 68 63 (52–73) vs. 65 (54–75) 100 30.0 (23.7–36.4) vs. 27.9 (22.6–33.2) Madueke-Laveaux et al.: AIRSEAL ® group 10mmHg/15mmHg and control group 10mmHg/15mmHg Desroches et al.: AIRSEAL ® group 12mmHg/15mmHg and control group 15mmHg Feng et al.: AIRSEAL ® group 12mmHg/15mmHg and control group 15mmHg Paull et al.: 4 groups Low anterior resection with traditional system versus AIRSEAL ® and right hemicolectomies with traditional system versus AIRSEAL ® Results are expressed by mean ± standard deviation, median (min; max) or median (interquartile range) LAR low anterior resection, PNRCT prospective non randomized clinical trials, Retro Retrospective, RCT Randomized Clinical Trials, na no data available
Description of the included studies and patients by specialties
2011
USA
Herati et al.
[ 25 ]
20,888,033
Urology
Yes
PNRCT
61.6 ± 14.2 vs.
59.7 ± 14.3
2013
Switzerland
Horstmann et al.
[ 2 ]
23,186,377
Urology
Yes
PNRCT
2015
USA
George et al.
[ 26 ]
25,725,807
Urology
Yes
Retro
27.6 (16.2–47.4) vs.
27.3 (17.8–41.4)
2016
USA
Bucur et al.
[ 1 ]
27,130,263
Urology
Yes
RCT
62.5 (15.3) vs.
64.8 (13.1)
27.9 (6.2) vs.
28.7 (4.1)
2017
Italy
Annino et al.
[ 22 ]
27,495,337
Urology
Yes
PNRCT
2017
Italy
Covotta et al.
[ 21 ]
28,452,822
Urology
Yes
RCT
60.2 (6.5) vs.
61.1 (9.1)
25.9 (3.5) vs.
26.5 (3.9)
2019
USA
Shahait et al.
[ 19 ]
30,740,014
Urology
Yes
PNRCT
2021
USA
Feng et al.
[ 8 ]
32,632,561
Urology
Yes
RCT
31 vs. 31
31
60.1 (11) vs.
61.0 (11.6)
/ 60.4 (12)
39 vs. 39
/ 42
30.0 (5.2) vs.
28.7 (5.7)
/ 31.0 (5.31)
2021
USA
Abaza et al.
[ 9 ]
33,349,135
Urology
Yes
RCT
61 ± 5.6 vs.
62 ± 6.7
2021
USA
Desroches et al.
[ 10 ]
33,577,899
Urology
Na
RCT
66 vs. 66
69
60.1 (13.3) vs.
60 (12.5)
/ 60.1 (11.8)
35 vs. 35
/ 38
29.2 (6.0) vs.
28.9 (5.6)
/ 31.2 (5.6)
2023
Lebanon
Ayoub et al.
[ 14 ]
37,704,868
Urology
Yes
Retro
65.1 ± 6.6 vs.
63.7 ± 7.3
2023
Italy
Forte et al.
[ 15 ]
37,440,928
Urology
Yes
Retro
2024
China
Wei et al.
[ 17 ]
38,381,369
Urology
Yes
RCT
53 (48; 64) vs.
57 (44; 63)
25.4 (22.7–27.7) vs.
24.3 (22.6–27.0)
2024
USA
Chien et al.
[ 16 ]
37,819,689
Urology
No
Retro
17.3 (16.4–22.3) vs.
16.5 (15.0–19.1)
2016
Japan
Miyano et al.
[ 23 ]
28,029,370
Abdominal
No
PNRCT
2021
USA
Paull et al.
[ 7 ]
32,333,365
Abdominal
Yes
Retro
LAR
Right hemicolectomy
40 vs. 54
24 vs. 32
55.2 ± 15.4 vs.
58.4 ± 9.7
55.5 ± 18.2 vs.
64.2 ± 13.2
55.0 vs. 42.6
70.8 vs. 46.9
27.9 ± 7.8 vs. 28.4 ± 6.5
29.7 ± 7.5 vs. 29.1 ± 7.3
2021
Austria
Luketina et al.
[ 11 ]
32,767,145
Abdominal
No
RCT
Cholecystectomy
Sigmoid resection
54.0 ± 12.9 vs.
55.2 ± 13.2
27.4 (24.6–31.0) vs.
27.8 (24.8–30.1)
2017
France
Sroussi et al.
[ 20 ]
28,403,972
Gynecology
No
RCT
Tubal patency test
Salpingectomy
33 (19–45) vs.
35 (25–58)
2020
USA
Madueke-Laveaux et al.
[ 18 ]
31,125,720
Gynecology
No
RCT
Uterine myomas
Endometriosis
33 vs.33
33 vs.33
40 ± 9 vs. 40 ± 7
39 ± 7 vs. 36 ± 8
27 ± 6 vs. 28
28 ± 7 vs. 27
2022
France
Delecourt et al.
[ 13 ]
35,569,811
Gynecology
No
RCT
25.3 (9.3) vs.
25.5 (5.5)
2022
Italy
Buda et al.
[ 12 ]
35,327,010
Gynecology
Yes
Retro
63 (52–73) vs.
65 (54–75)
Madueke-Laveaux et al.: AIRSEAL ® group 10mmHg/15mmHg and control group 10mmHg/15mmHg
Desroches et al.: AIRSEAL ® group 12mmHg/15mmHg and control group 15mmHg
Feng et al.: AIRSEAL ® group 12mmHg/15mmHg and control group 15mmHg
Paull et al.: 4 groups Low anterior resection with traditional system versus AIRSEAL ® and right hemicolectomies with traditional system versus AIRSEAL ®
Results are expressed by mean ± standard deviation, median (min; max) or median (interquartile range)
LAR low anterior resection, PNRCT prospective non randomized clinical trials, Retro Retrospective, RCT Randomized Clinical Trials, na no data available
Table 2 Description of the laparoscopic outcomes Authors + PMID Specialty Robotic surgery Operative duration (min) AIRSEAL ® vs. Control Intra-abdominal pressure (mmHg) α AIRSEAL ® vs. Control CO 2 absorption rate (ml/kg/min) α AIRSEAL ® vs. Control End-tidal CO 2 (mmHg) α AIRSEAL ® vs. Control Volume of CO 2 (L) α AIRSEAL ® vs. Control Herati et al. [ 25 ] 20,888,033 Urology No 123 ± 43 vs. 146 ± 55 15 vs. 15 Na vs. na Na vs. na 111.7 ± 77.3 vs. 306.4 ± 218.5*** Horstmann et al. [ 2 ] 23,186,377 Urology Yes 175 (111–297) vs. 166 (113–276) 12 vs. 12 Na vs. na Na vs. na 1205 (400–2578) vs. 1044 (245–1674) George et al. [ 26 ] 25,725,807 Urology Yes 150 (45–325) vs. 170 (65–340) *** 10 vs. 12 Na vs. na Na vs. na Na vs. na Bucur et al. [ 1 ] 27,130,263 Urology No 151 (48) vs. 130 (35) 14.0 ± 1.3 vs. 14.7 ± 1.7 Na vs. na Na vs. na Na vs. na Annino et al. [ 22 ] 27,495,337 Urology Yes 140 vs. 157* 12 vs. 12 Na vs. na Na vs. na Na vs. na Covotta et al. [ 21 ] 28,452,822 Urology Yes 372 (77) vs. 344 (81) 12.4 ± 0.24 vs. 11.8 ± 0.18 4.2 ± 0.3 vs. 5.4 ± 0.3** 28.8 ± 0.5 vs. 31.3 ± 0.5** Na vs. na Shahait et al. [ 19 ] 30,740,014 Urology Yes 146 ± 35 vs. 167 ± 25** 15 vs. 15 Na vs. na Na vs. na Na vs. na Feng et al. [ 8 ] 32,632,561 Urology Yes Na vs. na 9.7 (1.8) / 11.4 (2.8) vs. 12.5 (3.2) Na vs. na Na vs. na Na vs. na Abaza et al. [ 9 ] 33,349,135 Urology Yes 159 vs. 153 6 vs. 6 Na vs. na 34.8 (15–46) vs. 34.2 (20–50) Na vs. na Desroches et al. [ 10 ] 33,577,899 Urology Yes Na vs. na 12 / 15 vs. 15 Na vs. na 33.9 (3.4)** / 35.0 (3.1) vs. 36.1 (4.1) Na vs. na Ayoub et al. [ 14 ] 37,704,868 Urology Yes 304 ± 45 vs. 317 ± 54 10 vs. 12 Na vs. na Na vs. na Na vs. na Forte et al. [ 15 ] 37,440,928 Urology na 109 vs. 121 12 vs. 12 Na vs. na Na vs. na Na vs. na Wei et al. [ 17 ] 38,381,369 Urology Yes 90 (90–128) vs. 100 (90–130) 12 vs. 15 Na vs. na 41 (36–44) vs. 45 (40–47)** Na vs. na Chien et al. [ 16 ] 37,819,689 Urology Mixed 237 (216–272) vs. 219 (191–245) 8 to 10 vs. 8 to 10 Na vs. na 39.1 (2.79) vs. 38.6 (3.01) Na vs. na Miyano et al. [ 23 ] 28,029,370 Abdominal no 72 ± 30 vs. 76 ± 32 7.9 ± 1.5 vs. 9 ± 1.2* Na vs. na 35.7 ± 3.7 vs. 38.5 ± 2.6* Na vs. na Paull et al. [ 7 ] 32,333,365 Abdominal Yes 185 ± 41 / 232 ± 75 vs. 192 ± 56 / 293 ± 92 Na vs. na Na vs. na Na vs. na Na vs. na Luketina et al. [ 11 ] 32,767,145 Abdominal No 71 (56–94) vs. 69 (52–93) 12 vs. 12 Na vs. na Na vs. na Na vs. na Sroussi et al. [ 20 ] 28,403,972 Gynecology No 26 (9–83) vs. 30 (10–85) 7 vs. 15 Na vs. na 36 (31–41) vs. 40 (33–46)*** Na vs. na Madueke-Laveaux et al. [ 18 ] 31,125,720 Gynecology Mixed 146 ± 79 / 141 ± 70 vs. 143 ± 73 / 129 ± 73 10 / 15 vs. 10 / 15 4 ± 1.1 vs. 4 ± 1.1 Na vs. na Na vs. na Delecourt et al. [ 13 ] 35,569,811 Gynecology No 147 (69) vs. 147 (77) 8 to 10 vs. 12 to 15 Na vs. na Na vs. na Na vs. na Buda et al. [ 12 ] 35,327,010 Gynecology No 113 (92–134) vs. 119 (84–154) 8.5 (7.5–9.5) vs. 11.3 (10.2–12.4) Na vs. na 33.7 (31.4–36.0) vs. 35.8 (32.3–39.3)*** 34.1 (29.9–38.3) vs. 47.9 (41.7–54.1)*** Madueke-Laveaux et al.: AIRSEAL ® group 10mmHg/15mmHg and control group 10mmHg/15mmHg Desroches et al.: AIRSEAL ® group 12mmHg/15mmHg and control group 15mmHg Feng et al.: AIRSEAL ® group 12mmHg/15mmHg and control group 15mmHg Paull et al.: 4 groups Low anterior resection with traditional system versus AIRSEAL ® and right hemicolectomies with traditional system versus AIRSEAL ® Results are expressed by mean ± standard deviation, median (min; max) or median (interquartile range), * p < 0.05, ** p < 0.01, and *** p < 0.001 (p values from included publications) α: These data were not included in the PICO framework but were reported for completeness. na not available
Description of the laparoscopic outcomes
Herati et al.
[ 25 ]
20,888,033
Horstmann et al.
[ 2 ]
23,186,377
George et al.
[ 26 ]
25,725,807
Bucur et al.
[ 1 ]
27,130,263
Annino et al.
[ 22 ]
27,495,337
Covotta et al.
[ 21 ]
28,452,822
Shahait et al.
[ 19 ]
30,740,014
Feng et al.
[ 8 ]
32,632,561
9.7 (1.8)
/ 11.4 (2.8) vs. 12.5 (3.2)
Abaza et al.
[ 9 ]
33,349,135
Desroches et al.
[ 10 ]
33,577,899
Ayoub et al.
[ 14 ]
37,704,868
Forte et al.
[ 15 ]
37,440,928
Wei et al.
[ 17 ]
38,381,369
Chien et al.
[ 16 ]
37,819,689
Miyano et al.
[ 23 ]
28,029,370
Paull et al.
[ 7 ]
32,333,365
185 ± 41 / 232 ± 75 vs. 192 ± 56
/ 293 ± 92
Luketina et al.
[ 11 ]
32,767,145
Sroussi et al.
[ 20 ]
28,403,972
Madueke-Laveaux et al.
[ 18 ]
31,125,720
146 ± 79 / 141 ± 70 vs. 143 ± 73
/ 129 ± 73
Delecourt et al.
[ 13 ]
35,569,811
Buda et al.
[ 12 ]
35,327,010
Madueke-Laveaux et al.: AIRSEAL ® group 10mmHg/15mmHg and control group 10mmHg/15mmHg
Desroches et al.: AIRSEAL ® group 12mmHg/15mmHg and control group 15mmHg
Feng et al.: AIRSEAL ® group 12mmHg/15mmHg and control group 15mmHg
Paull et al.: 4 groups Low anterior resection with traditional system versus AIRSEAL ® and right hemicolectomies with traditional system versus AIRSEAL ®
Results are expressed by mean ± standard deviation, median (min; max) or median (interquartile range), * p < 0.05, ** p < 0.01, and *** p < 0.001 (p values from included publications)
α: These data were not included in the PICO framework but were reported for completeness.
na not available
Ten were conducted in the United States [ 1 , 7 – 10 , 16 , 18 , 19 , 24 , 25 ], while the remaining 11 originated from eight European centers [ 2 , 11 – 13 , 15 , 20 – 22 ], two Asian centers [ 17 , 23 ], and one Lebanon center [ 14 ]. Ten were randomized controlled trials (RCTs) [ 1 , 8 – 11 , 13 , 17 , 18 , 20 , 21 ], five were prospective non-RCTs [ 2 , 19 , 22 , 23 , 25 ], and six were retrospective cohort studies [ 7 , 12 , 14 – 16 , 24 ]. Only two studies were multicenter, which may account for the relatively small sample sizes (fewer than 100 patients) reported in 52% of the studies.
Fourteen studies involved patients undergoing urologic procedures [ 1 , 2 , 8 – 10 , 14 – 17 , 19 , 21 , 22 , 24 , 25 ], 11 of which employed robotic-assistance [ 2 , 8 – 10 , 14 , 16 , 17 , 19 , 21 , 22 , 24 ]. The remaining seven studies included four gynecologic [ 12 , 13 , 18 , 20 ] and three abdominal surgery cohorts [ 7 , 11 , 23 ]. Most surgeries were performed for oncologic indications, except in six studies.
Of the ten RCTs, six [ 8 , 11 , 13 , 17 , 18 , 21 ] were rated as high quality, while four were deemed of fair [ 1 , 10 , 20 ] or poor [ 9 ] quality (Appendix 2). The primary limitations included inadequate description of randomization procedures, or concerns about potential allocation or concealment bias.
Of the 11 non-RCTs, two [ 19 , 24 ] were rated of fair quality, and 9 were judged of poor quality (Appendix 2). Common shortcomings involved incomplete reporting of baseline characteristics and study objectives, insufficient detail in statistical methods, and limited sample sizes.
Overall, only six studies achieved a good quality rating, with the remainder deemed of fair ( n = 5) or poor ( n = 10) quality.
Across all included studies, 2804 participants were enrolled, with 1,354 allocated to AIRSEAL ® groups and 1,450 to control groups. Baseline characteristics were generally balanced between groups, including proportions of female participants (excluding single-sex studies) ranging from 17.8% to 70.8% in AIRSEAL ® groups vs. 25.4% to 54.6% in controls. Age ranged from 8.8 to 66.3 years vs. 8.8 to 65.9 years respectively, and body mass index (BMI) ranges were 17.0–31.2 kg/m² and 16.5–29.3 kg/m² respectively.
Reported pneumoperitoneum pressures varied between 5 and 15 mmHg in AIRSEAL ® groups and between 5 and 15 mmHg in control groups [ 2 , 8 – 25 ].
Table 3 Description of the perioperative blood loss, total complications, general pain and shoulder pain scores at 24-h, and hospital length of stay Authors PMID Specialty Blood loss (ml) AIRSEAL ® vs. Control Total complications (%) AIRSEAL ® vs. Control General pain scores at 24-h (NRS) AIRSEAL ® vs. Control Shoulder pain scores at 24-h (NRS) AIRSEAL ® vs. Control Hospital length of stay (days) AIRSEAL ® vs. Control Herati et al. [ 25 ] 20,888,033 Urology 304 (100; 800) vs. 319 (50; 1700) 11.5 vs. 8 Na vs. na Na vs. na 2.6 ± 1.1 vs. 2.2 ± 1.0 Horstmann et al. [ 2 ] 23,186,377 Urology 290 (100; 1200) vs. 215 (100; 450) 26.3 vs. 5.9* Na vs. na Na vs. na Na vs. na George et al. [ 26 ] 25,725,807 Urology 257 (0; 2000) vs. 224 (0; 1500) 0.5 vs. 0.8 Na vs. na Na vs. na Na vs. na Bucur et al. [ 1 ] 27,130,263 Urology 155 ± 168 vs. 75 ± 91* 17.9 vs. 35.7 3.7 ± 2.2 vs. 3.8 ± 2.1 1.6 ± 2.1 vs. 1.9 ± 2.6 2.2 ± 1.2 vs. 2.5 ± 1.1 Annino et al. [ 22 ] 27,495,337 Urology Na vs. na 10.4 vs. 16.4 Na vs. na Na vs. na Na vs. na Covotta et al. [ 21 ] 28,452,822 Urology 448 ± 302 vs. 485 ± 315 Na vs. na Na vs. na Na vs. na Na vs. na Shahait et al. [ 19 ] 30,740,014 Urology 133 ± 66 vs. 144 ± 58 5 vs. 4 2.2 vs. 3.4 Na vs. na 1 ± 1 vs. 1 ± 0 Feng et al. [ 8 ] 32,632,561 Urology Na vs. na Na vs. na Na vs. na Na vs. na 1.3 (0.7) / 1.1 (0.3) vs. 1.2 (0.4) Abaza et al. [ 9 ] 33,349,135 Urology 146.5 vs. 126.5* Na vs. na Na vs. na Na vs. na 0.4 vs. 0.3 Desroches et al. [ 10 ] 33,577,899 Urology Na vs. na Na vs. na Na vs. na Na vs. na Na vs. na Ayoub et al. [ 14 ] 37,704,868 Urology 270 ± 156 vs. 235.5 ± 120 13.6 vs. 13.9 Na vs. na Na vs. na 1.5 ± 0.1 vs. 2.0 ± 0.1*** Forte et al. [ 15 ] 37,440,928 Urology Na vs. na 0 vs. 7.7 Na vs. na Na vs. na Na vs. na Wei et al. [ 17 ] 38,381,369 Urology 50 (20–50) vs. 50 (20–50) Na va na Na- vs. na Na vs. na 5 (4 6) vs. 5 (4; 6) Chien et al. [ 16 ] 37,819,689 Urology 22.5 (2.5–47.5) vs. 25.0 (5.0–25.0) 7.1 vs. 16.7 Na vs. na Na vs. na 1 (1–2) vs. 1 (1–2) Miyano et al. [ 23 ] 28,029,370 Abdominal 4 ± 3 vs. 4 ± 2 5.6 vs. 0 Na vs. na Na vs. na 4.3 ± 2.3 vs. 3.8 ± 1.1 Paull et al. [ 7 ] 32,333,365 Abdominal 135 ± 183.1 / 150 ± 173 vs. 156 ± 209 / 209 ± 189 12.5 / 8.3 vs. 9.3 / 6.3 Na vs. na Na vs. na 3.8 ± 1.5 / 4.3 ± 3.1 vs. 4.9 ± 2.4 / 4.6 ± 3.7 Luketina et al. [ 11 ] 32,767,145 Abdominal Na vs. na 6.2 vs. 6.3 Na vs. na 2.7 (0–8) vs. 1.5 (0–6)*** 3.50 (3–4.5) vs. 4 (3–5) Sroussi et al. [ 20 ] 28,403,972 Gynecology Na vs. na Na vs. na Na vs. na 0.5 (0; 6) vs. 1.5 (0; 6)** Na vs. na Madueke-Laveaux et al. [ 18 ] 31,125,720 Gynecology 178 ± 169 / 113 ± 130 vs. 235 ± 365 / 186 ± 271 3.0 / 3.0 vs. 9.1 / 0 Na vs. na 0 / 0 vs. 0 / 0 Na vs. na Delecourt et al. [ 13 ] 35,569,811 Gynecology 100 (150) vs. 100 (163) 2.5 vs. 0 Na vs. na 1.27 ± 2,7 vs. 0.48 ± 1.1 4 (1) vs. 4 (1) Buda et al. [ 12 ] 35,327,010 Gynecology 122.0 (77.6–166.4) vs. 121.0 (79.6–162.4) 0 vs. 2.9 0.2 (0–0.8) vs. 1.1 (0.2-2.0)*** Na vs. na 2.0 (1.4–2.6) vs. 2.2 (1.4–3.0) Madueke-Laveaux et al.: AIRSEAL ® group 10mmHg/15mmHg and control group 10mmHg/15mmHg Desroches et al.: AIRSEAL ® group 12mmHg/15mmHg and control group 15mmHg Feng et al.: AIRSEAL ® group 12mmHg/15mmHg and control group 15mmHg Paull et al.: 4 groups Low anterior resection with traditional system versus AIRSEAL ® and right hemicolectomies with traditional system versus AIRSEAL ® Results are expressed by mean ± standard deviation, median (min; max) and median (interquartile range) na not available, NRS numeric rating scale * p < 0.05, ** p < 0.01, and *** p < 0.001 (p values from included publications)
Description of the perioperative blood loss, total complications, general pain and shoulder pain scores at 24-h, and hospital length of stay
Herati et al.
[ 25 ]
20,888,033
Horstmann et al.
[ 2 ]
23,186,377
George et al.
[ 26 ]
25,725,807
Bucur et al.
[ 1 ]
27,130,263
Annino et al.
[ 22 ]
27,495,337
Covotta et al.
[ 21 ]
28,452,822
Shahait et al.
[ 19 ]
30,740,014
Feng et al.
[ 8 ]
32,632,561
Abaza et al.
[ 9 ]
33,349,135
Desroches et al.
[ 10 ]
33,577,899
Ayoub et al.
[ 14 ]
37,704,868
Forte et al.
[ 15 ]
37,440,928
Wei et al.
[ 17 ]
38,381,369
Chien et al.
[ 16 ]
37,819,689
Miyano et al.
[ 23 ]
28,029,370
Paull et al.
[ 7 ]
32,333,365
Luketina et al.
[ 11 ]
32,767,145
Sroussi et al.
[ 20 ]
28,403,972
Madueke-Laveaux et al.
[ 18 ]
31,125,720
Delecourt et al.
[ 13 ]
35,569,811
Buda et al.
[ 12 ]
35,327,010
Madueke-Laveaux et al.: AIRSEAL ® group 10mmHg/15mmHg and control group 10mmHg/15mmHg
Desroches et al.: AIRSEAL ® group 12mmHg/15mmHg and control group 15mmHg
Feng et al.: AIRSEAL ® group 12mmHg/15mmHg and control group 15mmHg
Paull et al.: 4 groups Low anterior resection with traditional system versus AIRSEAL ® and right hemicolectomies with traditional system versus AIRSEAL ®
Results are expressed by mean ± standard deviation, median (min; max) and median (interquartile range)
na not available, NRS numeric rating scale
* p < 0.05, ** p < 0.01, and *** p < 0.001 (p values from included publications)
Postoperative pain, including general or shoulder pain, was evaluated in 10 studies [ 1 , 8 , 10 – 13 , 17 – 20 ]. There was heterogeneity across studies in terms of time points to assess pain (2 h postoperatively, 6 h, 24 h, etc.). We chose to report here pain measurements at 24 h, which was the time point the most frequently described and deemed of greater relevance, while other outcomes are available in Appendix 3.
Of these, five reported a statistically significant reduction in shoulder pain [ 8 , 10 – 12 , 20 ] and three in general pain [ 12 , 17 , 19 ] after surgery in the AIRSEAL ® group compared to standard insufflation. The remaining studies found no significant differences in postoperative pain scores between groups.
Regarding analgesic consumption, of the six studies that assessed the use of analgesic [ 1 , 8 , 9 , 12 , 14 , 20 ], three [ 12 , 14 , 20 ] reported a significant reduction at 24 h postoperatively in patients treated with AIRSEAL ® compared to the control group while in the three others [ 1 , 8 , 9 ] no significant difference was observed.
Fourteen studies [ 1 , 2 , 7 , 10 , 11 , 13 , 14 , 16 , 18 , 19 , 22 – 25 ] reported the overall complication rates within 30 days post-surgery. In the majority of these, complication rates were comparable between the AIRSEAL ® and the control groups [ 1 , 7 , 11 , 13 , 14 , 16 , 18 , 19 , 22 – 25 ]. Two studies reported discrepant findings with one [ 2 ] where a higher incidence of total complications was found in the AIRSEAL ® group, specifically subcutaneous emphysema ( p < 0.05), while in another study [ 10 ] a lower incidence of subcutaneous emphysema was shown in the AIRSEAL group ( p < 0.05).
The rate of severe complications (Clavien–Dindo grade ≥ 2 ), which was reported in four studies [ 2 , 10 , 11 , 13 ], did not differ between groups.
Intraoperative blood loss was measured in 15 studies [ 1 , 2 , 7 , 9 , 10 , 12 – 14 , 16 – 19 , 23 – 25 ], showing ranges from 3.6 to 448 ml in the AIRSEAL ® groups vs. 3.5 to 485 ml in control groups. In 11 of these [ 2 , 10 , 12 , 13 , 16 – 19 , 23 – 25 ], no difference was found between groups. Three studies [ 1 , 9 , 14 ] reported a statistically significant increase in blood loss in the AIRSEAL ® group whereas in one study [ 7 ], authors showed a decrease in blood loss in the AIRSEAL ® group. Postoperative blood transfusion rates were similar across groups in five studies [ 11 , 14 , 15 , 22 , 24 ].
Conversion to laparotomy was a rarely reported outcome (five studies [ 11 , 13 , 15 , 18 , 24 ]) and appeared to be of exceptional occurrence with no difference between groups.
None of the studies included outcomes on 30-day hospital readmission rates.
Operative times varied between 26 and 372 min in the AIRSEAL ® groups compared to 30 to 344 min in the control groups. Five studies [ 7 , 14 , 19 , 22 , 24 ] reported shorter operative durations with AIRSEAL ® compared to control groups. Eleven studies found no difference in operative duration between groups [ 8 , 9 , 11 – 13 , 16 , 17 , 20 , 21 , 23 , 24 ], and two studies did not provide statistical analysis on this variable [ 15 , 18 ].
Postoperative room stay was reported in three studies [ 8 , 18 , 21 ], with durations ranging from 127 to 260 min in the AIRSEAL ® group and 147 to 285 min in control groups. Hospital length of stay was assessed in 13 studies [ 1 , 7 – 9 , 11 – 14 , 16 , 17 , 19 , 23 , 25 ], with median stays ranging from 0.4 to 5 days for AIRSEAL ® patients and 0.3 to 5 days for controls. No significant differences were found between groups for either postoperative room stay or overall hospitalization time.
None of the included studies reported data on the costs associated with surgical management.
Discussion
To date, most data on the safety and feasibility of the AIRSEAL ® system are derived from studies conducted in urologic surgery, but also from gynecologic and digestive surgery. Our previous review reported no significant differences between groups in terms of overall complication rates, post-anesthesia care unit stay, or total length of hospitalization, and findings related to postoperative pain were inconsistent [ 3 ].
The objective of this work was to provide an updated and critical assessment of the existing literature on the use of the AIRSEAL ® device in laparoscopic and robotic surgeries, based on patient and organizational outcomes. This evaluation was considered necessary given the increasing adoption of the AIRSEAL ® system in surgical practices, despite its relatively high per-procedure cost. Moreover, the lack of a formal health technology assessment highlights the need for evidence-based insights to support institutional decision-making.
With regard to blood loss, most studies did not find significant differences between groups. Three studies reported increase blood loss in the AIRSEAL ® group [ 1 , 9 , 14 ]; however, given the overall low volumes involved, the clinical relevance of such differences remains questionable, transfusion was required in only one study [ 14 ] without difference between groups.
Regarding conversions to laparotomy, few studies reported this outcome, and when it was mentioned, the underlying causes, such as difficulties to obtain a correct exposure or other intraoperative challenges, were rarely detailed.
Finally, operative times were not prolonged in the studies reviewed; in fact, five studies reported a reduction in surgical duration [ 7 , 14 , 19 , 22 , 24 ]. We may speculate that the improvement of visualization, reduced need for lens cleaning, and greater pneumoperitoneum stability with the use of the AIRSEAL ® device. Nevertheless, although a reduced operative time was observed in five of the studies with the largest sample sizes, the data remain heterogeneous, and most studies do not demonstrate any significant difference in operative duration.
Regarding overall postoperative complications, no significant differences was observed between groups using the AIRSEAL ® device and those using conventional insufflation. However, findings related to subcutaneous emphysema remain inconsistent: while one study reported an increased incidence in the AIRSEAL ® group [ 2 ], another found a decreased occurrence [ 10 ]. In contrast, few studies have specifically examined the rate of severe complications, defined as Clavien-Dindo grade ≥ 2. No significant differences in the occurrence of these severe complications between the AIRSEAL ® and conventional insufflation groups were found.
Postoperative pain was considered one of the most clinically relevant outcomes to evaluate the potential benefit of AIRSEAL ® device. However, findings on postoperative pain were not consistent: about half of the studies found no significant difference, while the other half reported a reduction in shoulder pain [ 8 , 10 – 12 , 20 ], which is a common complaint following laparoscopic surgery but its etiology is not well understood. Similarly, postoperative analgesic consumption was reported as either comparable between groups in three out of six studies [ 1 , 8 , 9 ] or reduced in the others [ 12 , 14 , 20 ]. However, despite a trend toward reduced pain and analgesic consumption, the length of hospital stay was similar between groups in all 13 studies that assessed this outcome.
Intraoperative data reported in the studies include parameters related to pneumoperitoneum, ventilatory variables, blood loss, and conversion to laparotomy. Elevated CO₂ absorption has been associated with several factors, including higher insufflation pressures, extended duration of pneumoperitoneum, gas leakage around trocars, and the presence of subcutaneous emphysema [ 25 ]. Increased CO₂ uptake during surgery can lead to clinically significant consequences, such as respiratory acidosis and, in rare cases, gas embolism [ 26 ]. Among the selected studies, only three have directly assessed total CO₂ consumption, with two studies reporting a lower volume use in the AIRSEAL ® group. Additionally, six studies reported reduced end-tidal CO₂ (EtCO₂) levels, although only one study simultaneously evaluated both CO 2 consumption and EtCO 2 , showing reductions in both parameters. Based on findings from this single study, we further hypothesize an improvement in physiologic tolerance to laparoscopy. However, very limited data are available on these parameters, and the existing evidence is highly heterogeneous. Therefore, larger-scale studies will be necessary to properly assess these outcomes and to confirm, or refute, any improvement in physiological tolerance associated with the AIRSEAL ® system. Variations in intra-abdominal pressure and prolonged Trendelenburg positioning may further increase the amount of CO₂ that needs to be eliminated by the body over the course of the procedure. However, the Trendelenburg position is commonly used in urologic and gynecologic surgeries, which represent the majority of the studies included in this review. This could partly explain why no significant differences, or only minimal differences in a few studies, were observed.
Ultimately, an important factor in the decision to change clinical practice, particularly the adoption of a new device, is the presence of economic evaluations. Indeed, the cost of an expensive device could be in theory offset by substantial savings due to reduction of resource use and/or substantial clinical benefit. Despite the substantial cost of the AIRSEAL ® device, it is noteworthy that no study has yet conducted such an evaluation.
Although this systematic review was conducted in accordance with PRISMA guidelines, it has several limitations. The primary one concerns the overall quality of the studies included: of the 21 studies analyzed, only 10 were RCTs, and among these, only six were of high quality. Moreover, the sample sizes of the included studies are limited, as only two were multicenter RCTs. The second limitation is that all types of laparoscopic surgeries were included, which may have introduced heterogeneity in the outcomes such as operative time, blood loss, and others. Another limitation is that no formal assessment of the certainty of evidence (e.g., GRADE) was performed, as our main objective was to provide a synthesis of the available literature based on patient outcomes and organizational impact rather than to formulate clinical practice recommendations. Nevertheless, this work may provide an evidence base for future guideline development using formal evidence appraisal methods. Finally, the outcomes included in this review were predefined according to the PICO framework and focused on patient outcomes and organizational endpoints. Consequently, surgeon-centered outcomes, such as perceived operative comfort, pneumoperitoneum stability, ease of specimen retrieval, or overall user experience, were not evaluated. These correspond to practical advantages of the AIRSEAL ® device, including reduced fogging, decreased need for repeated lens cleaning, and a smoother overall operative course. Such outcomes represent important determinants of the perceived value of valve-less insufflation systems and should be assessed in future reviews using validated surgeon-reported outcome measures.
Nonetheless, our review offers a broad overview of the current literature, regardless of the specific surgical field. Additionally, we observed that many studies either lacked clinically relevant outcomes or reported them inconsistently often due to variations in outcome definitions or measurement time points. The absence of significant differences in most of clinical endpoints should not be interpreted as evidence of equivalence across all dimensions of performance, and that workflow-related advantages of valveless systems may not be fully captured by the outcomes analyzed in our review.